Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Congenica and Northern Health Science Alliance Announces Partnership

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
Partnership set to accelerate development of diagnostic tools and improve outcomes for patients.

Cambridge based Congenica Ltd and the UK Northern Health Science Alliance have announced a strategic partnership to deliver more accurate diagnostic tools and improve outcomes for patients with genetic conditions.

The aim of the partnership is to accelerate the development of collaborations between Congenica Ltd, a clinical genome diagnostics and discovery company, and that of the leading universities and NHS hospital Trusts in the North of England.

The first proof-of-principle agreement under the partnership has already been formed between Congenica Ltd and Central Manchester University Hospitals NHS Foundation Trust.

The overarching partnership will bring together clinical genetic expertise, molecular diagnostic testing and large-scale genome analytics to develop and implement the next generation sequencing based analysis pipelines, genome-wide interpretation and reporting tools for diagnostic testing. This unique system will be rolled out to a variety of different applications and available through service and licensing business models.

Congenica’s genome analytics platform, which is scalable and capable of processing many thousands of samples per year, is central to the partners’ ambitious plans.

Congenica’s genome analytics platform uses statistical and computational methods, and has the flexibility to evolve with the rapidly changing next generation sequencing technology and clinical applications.

Under the agreement between Congenica and Central Manchester University Hospitals NHS Foundation Trust, the partners will create a reference laboratory. Based at the Manchester Centre for Genomic Medicine, the reference laboratory will undertake genome screening of patients and their unaffected relatives in order to generate a comprehensive genetic profile and clinical report to support diagnosis, the clinical decision making, treatment choice, and counselling.

The partnership will concentrate efforts on developmental disorders, which account for approximately 30% of all genetic disease, but will then follow-on with programs in other therapeutic indications such as ophthalmological, cardiovascular and neurological disease.

“In 2001 the world witnessed the sequencing of the human genome, now in 2014 we are developing tools to help clinicians embed genomic medicine in the clinic. The partnership between Congenica and the Northern Health Science Alliance will further help us understand the utility of genomic medicine and bring the technology one step closer to routine clinical practice”, said Dr Hakim Yadi, Chief Executive of the Northern Health Science Alliance.

“Congenica is extremely pleased to enter into partnership with the NHSA and Central Manchester University Hospitals NHS Foundation Trust. The age of precision medicine is upon us and this is a great opportunity to bring together the wealth of clinical expertise and innovation at Manchester with our scalable genome analytics and clinical decision support tools”, said Dr Tom Weaver, CEO of Congenica. “We strongly believe that partnering is the best way to facilitate rapid adoption of our technology and make a real impact on tackling genetic disease in the clinic.”

Manchester Academic Health Science Centre partners, Central Manchester University Hospitals NHS Foundation Trust and The University of Manchester are renowned for their world-leading clinical and research expertise in genomic medicine. Together, they are founders of the Manchester Centre for Genomic Medicine (MCGM), an integrated academic and service department based at Central Manchester University Hospitals NHS Foundation Trust.

Professor Graeme Black, Strategic Director at the Manchester Centre for Genomic Medicine and Consultant in Genetics and Ophthalmology said: “Manchester was an early adopter of Next Generation Sequencing, and we provide clinical and diagnostic services for inherited disorders to a population of over six million individuals. We bring a wealth of diagnostic and clinical expertise in the diagnosis and management of rare diseases.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Congenica’s Diagnostic Technology Validated by Genomics England
Company selected as one of the winners of a whole genome annotation assessment.
Thursday, October 16, 2014
UK Genomics Medicine Start-up Congenica Ltd Wins Genomics England Competition
Funding to be used by Congenica to further develop it’s SAPIENTIA™ platform.
Tuesday, May 06, 2014
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!